Potent oncolytic activity of human enteroviruses against human prostate cancer

Prostate

Volumn 68, Issue 6, 2008, Pages 577-587

  Berry, Linda J ^a   Au, Gough G ^a   Barry, Richard D ^a   Shafren, Darren R ^a,b  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b Viralytics Ltd   (Australia)

Author keywords

Cellular receptors; Enteroviruses; Oncolysis; Virotherapy; Xenograft

Indexed keywords

ALPHA1 INTEGRIN; ALPHA2 INTEGRIN; ANDROGEN; ANTINEOPLASTIC AGENT; DECAY ACCELERATING FACTOR; INTERCELLULAR ADHESION MOLECULE 1; ONCOLYTIC COXSACKIE A21 DAF VIRUS; ONCOLYTIC COXSACKIE A21 VIRUS; ONCOLYTIC ECHOVIRUS 1; ONCOLYTIC VIRUS; VIRUS RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ADHESION; CELL CULTURE; CONTROLLED STUDY; CYTOLYSIS; DOSE RESPONSE; ENTEROVIRUS; FLOW CYTOMETRY; IMMUNE DEFICIENCY; MICROTITER PLATE ASSAY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SCID MOUSE; XENOGRAFT;

ANIMALS; ANTIGENS, CD55; CELL LINE, TUMOR; ENTEROVIRUS A, HUMAN; ENTEROVIRUS B, HUMAN; FLOW CYTOMETRY; HUMANS; INTEGRIN ALPHA2BETA1; INTERCELLULAR ADHESION MOLECULE-1; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, SCID; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PROSTATIC NEOPLASMS; SPECIFIC PATHOGEN-FREE ORGANISMS; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 42949155146     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20741     Document Type: Article

References (52)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun M. Cancer statistics, 2007. CA Cancer J Clin 2007;57(1):43-66.
2. Parato KA, Senger D, Forsyth PA, Bell JC. Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 2005;5(12):965-976.
3. Bell JC, Garson KA, Lichty BD, Stojdl DF. Oncolytic viruses: Programmable tumour hunters. Curr Gene Ther 2002;2(2):243-254.
4. Shafren DR, Au GG, Nguyen T, Newcombe NG, Haley ES, Beagley L, Johansson ES, Hersey P, Barry RD. Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus A21. Clin Cancer Res 2004;10(1 Pt 1):53-60.
5. Shafren DR, Sylvester D, Johansson ES, Campbell IG, Barry RD. Oncolysis of human ovarian cancers by echovirus type 1. Int J Cancer 2005;115:320-328.
6. Au GG, Lindberg AM, Barry RD, Shafren DR. Oncolysis of vascular malignant human melanoma tumors by Coxsackievirus A21. Int J Oncol 2005;26(6):1471-1476.
7. Shafren DR, Dorahy DJ, Ingham RA, Burns GF, Barry RD. Coxsackievirus A21 binds to decay-accelerating factor but requires intercellular adhesion molecule 1 for cell entry. J Virol 1997;71(6):4736-4743.
8. Johansson ES, Xing L, Cheng RH, Shafren DR. Enhanced cellular receptor usage by a bioselected variant of coxsackievirus a21. J Virol 2004;78(22):12603-12612.
9. Racaniello VR. Picornaviridae: The viruses and their replication. In: Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Riozman B, Straus SE, editors. Fields virology, 4th edition. 2001. pp. 685-722.
10. Bergelson JM, Shepley MP, Chan BM, Hemler ME, Finberg RW. Identification of the integrin VLA-2 as a receptor for echovirus 1. Science 1992;255(5052):1718-1720.
11. King SL, Cunningham JA, Finberg RW, Bergelson JM. Echovirus 1 interaction with the isolated VLA-2 I domain. J Virol 1995;69(5):3237-3239.
12. Marjomaki V, Pietiainen V, Matilainen H, Upla P, Ivaska J, Nissinen L, Reunanen H, Huttunen P, Hyypia T, Heino J. Internalization of echovirus 1 in caveolae. J Virol 2002;76(4):1856-1865.
13. Hubbard A, Rothlein R. Intercellular adhesion molecule-1 (ICAM-1) expression and cell signaling cascades. Free Radic Biol Med 2000;28(9):1379- 1386.
14. Liu AY, Roudier MP, True LD. Heterogeneity in primary and metastatic prostate cancer as defined by cell surface CD profile. Am J Pathol 2004;165(5):1543-1556.
15. Rokhlin OW, Cohen MB. Expression of cellular adhesion molecules on human prostate tumor cell lines. Prostate 1995;26(4):205-212.
16. Tomita Y, Watanabe H, Kobayashi H, Nishiyama T, Tsuji S, Imai K, Abo T, Fujiwara M, Sato S. Expression of intercellular adhesion molecule-1 on transitional cell cancer. Possible significance in immunity against tumor cells. Am J Pathol 1993;143(1):191-198.
17. Freedland SJ, Seligson DB, Liu AY, Pantuck AJ, Paik SH, Horvath S, Wieder JA, Zisman A, Nguyen D, Tso CL, Palotie AV, Belldegrun AS. Loss of CD10 (neutral endopeptidase) is a frequent and early event in human prostate cancer. Prostate 2003;55(1):71-80.
18. Aalinkeel R, Nair MP, Sufrin G, Mahajan SD, Chadha KC, Chawda RP, Schwartz SA. Gene expression of angiogenic factors correlates with metastatic potential of prostate cancer cells. Cancer Res 2004;64(15):5311-5321.
19. Liu AY. Differential expression of cell surface molecules in prostate cancer cells. Cancer Res 2000;60(13):3429-3434.
20. Donin N, Jurianz K, Ziporen L, Schultz S, Kirschfink M, Fishelson Z. Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid. Clin Exp Immunol 2003;131(2):254-263.
21. Fishelson Z, Donin N, Zell S, Schultz S, Kirschfink M. Obstacles to cancer immunotherapy: Expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol Immunol 2003;40(24):109-123.
22. Loberg RD, Wojno KJ, Day LL, Pienta KJ. Analysis of membrane-bound complement regulatory proteins in prostate cancer. Urology 2005;66(6):1321-1326.
23. Bonkhoff H, Stein U, Remberger K. Differential expression of alpha 6 and alpha 2 very late antigen integrins in the normal, hyperplastic, and neoplastic prostate: Simultaneous demonstration of cell surface receptors and their extracellular ligands. Hum Pathol 1993;24(3):243-248.
24. Bello D, Webber MM, Kleinman HK, Wartinger DD, Rhim JS. Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18. Carcinogenesis 1997;18(6):1215-1223.
25. Sobel R, Sadar M. Cell lines used in prostate cancer research: A compendium of old and new lines - Part 1. J Urol 2005;173(2):342-359.
26. Sobel RE, Sadar MD. Cell lines used in prostate cancer research: A compendium of old and new lines - Part 2. J Urol 2005;173(2):360-372.
27. Shafren DR, Bates RC, Agrez MV, Herd RL, Burns GF, Barry RD. Coxsackieviruses B1, B3, and B5 use decay accelerating factor as a receptor for cell attachment. J Virol 1995;69(6):3873-3877.
28. Schwerdt C, Fogh J. The ratio of physical particles per infectious unit observed for poliomyelitis viruses. Virology 1957;4(1):41-52.
29. Roizman B, Hopken W, Mayer M. Immunochemical studies of poliovirus. II. Kinetics of the formation of infectious and noninfectious type 1 poliovirus in three cell strains of human derivation. J Immunol 1958;80(5):386-395.
30. Mayer M, Rapp H, Roizman B, Klein S, Cowan K, Lukens D. The purification of poliomyelitis virus as studied by complement fixation. J Immunol 1957;78(6):435-455.
31. Coyne KE, Hall SE, Thompson S, Arce MA, Kinoshita T, Fujita T, Anstee DJ, Rosse W, Lublin DM. Mapping of epitopes, glycosylation sites, and complement regulatory domains in human decay accelerating factor. J Immunol 1992;149(9):2906-2913.
32. Boyd AW, Wawryk SO, Burns GF, Fecondo JV. Intercellular adhesion molecule 1 (ICAM-1) has a central role in cell-cell contact-mediated immune mechanisms. Proc Natl Acad Sci USA 1988;85(9):3095-3099.
33. Nyberg-Hoffman C, Shabram P, Li W, Giroux D, Aguilar-Cordova E. Sensitivity and reproducibility in adenoviral infectious titer determination. Nat Med 1997;3(7):808-811.
34. Mittereder N, March K, Trapnell B. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. Mol Ther 1996;70(11):7498-7509.
35. Liu AY, LaTray L, van Den Engh G. Changes in cell surface molecules associated with in vitro culture of prostatic stromal cells. Prostate 2000;44(4):303-312.
36. Liu A, True L. Characterization of prostate cell types by CD cell surface molecules. Am J Pathol 2002;160(1):37-43.
37. Wolff JM, Stephenson RN, Chisholm GD, Habib FK. Levels of circulating intercellular adhesion molecule-1 in patients with metastatic cancer of the prostate and benign prostatic hyperplasia. Eur J Cancer 1995;31(3):339-341.
38. Zhao H, Kim Y, Wang P, Lapointe J, Tibshirani R, Pollack J, Brooks J. Genome-wide characterization of gene expression variations and DNA copy number changes in prostate cancer cell lines. Prostate 2005;63(2):187-197.
39. Stuart A, Eustace H, McKee T, Brown T. A novel cell entry pathway for a DAF-using human enterovirus is dependent on lipid rafts. Mol Ther 2002;76(18):9307-9322.
40. Shafren D. Viral cell entry induced by cross-linked decay-accelerating factor. J Virol 1998;72(11):9407-9412.
41. Williams T, Lisanti M. Caveolin-1 in oncogenic transformation, cancer, and metastasis. Am J Physiol Cell Physiol 2005;288(3):C494-C506.
42. Karam J, Lotan Y, Roehrborn C, Ashfaq R, Karakiewicz P, Shariat S. Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence. Prostate 2007;67(6):614-622.
43. Schommer S, Carpenter S, Paul P. Comparison of porcine reproductive and respiratory syndrome virus growth in media supplemented with fetal bovine serum or a serum replacement. J Vet Diagn Invest 2001;13(3):276-279.
44. Waite M, Pfefferkorn E. Inhibition of Sindbis virus production by media of low ionic strength: Intracellular events and requirements for reversal. Mol Ther 1970;5(1):60-71.
45. Ashkenazi A, Melnick JL. Topics in microbiology. Enteroviruses - A review of their properties and associated diseases. Am J Clin Pathol 1962;38:209-229.
46. Melnick J, Godman G. Pathogenesis of Coxsackie virus infection; multiplication of virus and evolution of the muscle lesion in mice. J Exp Med 1951;93(3):247-266.
47. Mufson M, Kawana R, Bloom H, Gorstein F, Chanock R. Pathogenicity of Coxsackie A-21 virus for suckling mice. Proc Soc Exp Biol Med 1968;128(1):237-246.
48. Phuangsab A, Lorence RM, Reichard KW, Peeples ME, Walter RJ. Newcastle disease virus therapy of human tumor xenografts: Antitumor effects of local or systemic administration. Cancer Lett 2001;172(1):27-36.
49. Wodarz D. Viruses as antitumor weapons: Defining conditions for tumor remission. Cancer Res 2001;61(8):3501-3507.
50. Karev GP, Novozhilov AS, Koonin EV. Mathematical modeling of tumor therapy with oncolytic viruses: Effects of parametric heterogeneity on cell dynamics. Biol Direct 2006;1:30.
51. Pereira MS, Pereira HG. Coe virus properties and prevalence in Great Britain. Lancet 1959;2:539.
52. Liu BL, Robinson M, Han ZQ, Branston RH, English C, Reay P, McGrath Y, Thomas SK, Thornton M, Bullock P, Love CA, Coffin RS. I CP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther 2003;10(4):292-303.